Skip to main content
BRAIN Biotech AG logo

BRAIN Biotech AG — Investor Relations & Filings

Ticker · BNN ISIN · DE0005203947 LEI · 391200JKPVHLD6JLZ107 F Professional, scientific and technical activities
Open in API
Filings indexed 368 across all filing types
Latest filing 2023-08-30 Earnings Release
Country DE Germany
Listing F BNN

About BRAIN Biotech AG

https://www.brain-biotech.com/

BRAIN Biotech AG is an industrial biotechnology company specializing in the discovery, development, and production of specialty enzymes, high-performance microorganisms, and bioactive compounds. The company provides tailor-made biosolutions and contract research and development (R&D) services to partners in the food, chemical, and life sciences sectors. Core competencies include enzyme technology, microbial strain development, and bioprocess development. By leveraging an advanced technology portfolio, which includes proprietary platforms for enzyme discovery and genome editing, the company enables its partners to create more sustainable and efficient industrial products and processes, contributing to the bioeconomy.

Recent filings

Filing Released Lang Actions
BRAIN Biotech AG reports solid 9M numbers despite ongoing high R&D investments and more challenging economic conditions
Earnings Release Classification · 95% confidence The document is a press release from BRAIN Biotech AG announcing their 9-month financial results. It provides key highlights, segment performance, and financial tables, but explicitly directs the reader to a separate link for the full '9M Report 2022/23'. Because it is a summary announcement of financial results rather than the full interim report itself, and it follows the standard format of an earnings release (ER) provided by a news distribution service, it is classified as an Earnings Release. 9M 2023
2023-08-30 English
Q3 statement / Q3 financial report 2022/2023
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Statement' for the period ending 30 June 2023. It contains comprehensive financial data, including consolidated income statements, balance sheets, cash flow statements, and detailed management analysis of financial performance and segment reporting. It is not an announcement of a report, but the report itself, and it covers a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. 9M 2023
2023-08-30 English
BRAIN Biotech AG s Akribion Genomics team successfully competes in Science4Life Venture Cup competition
Regulatory Filings Classification · 100% confidence The document is a press release dated June 28, 2023, disseminated via EQS News. It announces that a team associated with BRAIN Biotech AG won second place in the Science4Life Venture Cup competition for their CRISPR-based cell killing tools concept. This is not a standard regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). It is a general corporate announcement regarding an achievement and future spin-off plans. Since it does not fit into specific categories like M&A (TAR), Director's Dealing (DIRS), or Capital Change (CAP), and it is a general news item about corporate activity, the most appropriate fallback category is Regulatory Filings (RNS), which serves as a general announcement category for news that doesn't fit elsewhere, especially when distributed via a news service like EQS.
2023-06-28 English
Anniversary of BRAIN Biotech AG: 30 years for a bio-based future
Regulatory Filings Classification · 100% confidence The document is a press release dated June 19, 2023, announcing the 30th anniversary of BRAIN Biotech AG. It contains general corporate news, CEO commentary, and background information about the company's history, business segments, and stock listing details. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial report (IR, AR). Since it is a general corporate announcement disseminated via EQS News, and it doesn't fit into specific categories like Director's Dealing (DIRS), Dividend (DIV), or Management Changes (MANG), the most appropriate fallback category is Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings.
2023-06-19 English
BRAIN Biotech AG stays on solid growth path with H1 results and accelerates One-BioProducts strategy
Earnings Release Classification · 100% confidence The document explicitly states it is publishing its "half year results, 6M 2022/2023" and contains detailed financial tables comparing the current six months (6M 2022/23) to the previous year's six months (6M 2021/22). The keywords "Half Year Results/Half Year Report" are present. This clearly identifies the document as a comprehensive financial report for an interim period shorter than a year. This matches the definition for an Interim / Quarterly Report (IR). It is not an Earnings Release (ER) because it is a comprehensive report, not just the initial highlights, and it is not a 10-K as it covers only six months. H1 2023
2023-05-25 English
Halbjahresfinanzbericht nach WpHG für den Zeitraum vom 01.10.2022 bis zum 31.03.2023
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Halbjahresfinanzbericht' (Half-Year Financial Report) for BRAIN Biotech AG, covering the period from 01.10.2022 to 31.03.2023. It contains comprehensive financial statements, segment reporting, management discussion and analysis (Konzernzwischenlagebericht), and balance sheet data. It is not an announcement of a report, but the report itself, and it covers a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. H1 2023
2023-05-25 German

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.